Assignee
FUSION PHARMACEUTICALS INC
CA·2 granted patents·24 pending applications·20 citations·filing 2017–2025
Top patents by PatentIndex Score
26 records- 0192US10093741B1IGF-1R monoclonal antibodies and uses thereofFUSION PHARMACEUTICALS INC·Filed 2017·Granted Oct 9, 2018·20 cites·18 claims
- 0268US11446401B2Actinium-225 and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2019·Granted Sep 20, 2022·0 cites·1 claims
- 0368US2023270895A1Radioimmunoconjugates and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0466US2021290788A1Radioimmunoconjugates and dna damage and repair inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0563US2021290789A1Radioimmunoconjugates and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0659US2025001019A1Methods of treating cancerFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0759US2024350682A1Steap2-targeted compounds and use thereofFUSION PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0858US2025177581A1Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0958US2025387492A1Hsp90-targeting conjugates and formulations thereofFUSION PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1056US2020308286A1Methods, compositions, and kits for treatment of cancerFUSION PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1155US2024207455A1Combination comprising a neurotensin receptor binding compound and napoxFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1255US2024165280A1Methods for treatment of cancersFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1355US2024216550A1Combination comprising a neurotensin receptor binding compound and napoliFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1454US2024197927A1Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxelFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1554US2025121104A1Egfr-cmet-targeted compounds and uses thereofFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1654US2024207276A1Combination comprising a neurotensin receptor binding compound and folfirinoxFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1752US2022218836A1Endosialin-binding antibodyFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1851US2024285818A1Radioimmunoconjugates and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1949US2024139333A12,6-dichlorophenyl ester compounds and use thereofFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2046US2021395281A1Macrocyclic chelates and uses thereofFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2145US2023091468A1Sustained immunotherapyFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2244US2025114488A1Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2344US2025002576A1Claudin 18.2-binding antibodies and fragments thereofFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2443US2025099633A1Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapyFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2542US2023201384A1Fgfr3-targeted radioimmunoconjugates and uses thereofFUSION PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2640US2024139353A1Methods of treating cancerFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when FUSION PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →